Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680

DUBLIN, Oct. 10, 2023, Alkermes plc today announced plans to present new data related to ALKS 2680, the company ' s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy, at World Sleep Congress, taking...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials